China's Health Reform Will Nurture New Drugs, While Boosting Use Of Old Ones - PharmAsia Summit
This article was originally published in The Pink Sheet Daily
Executive Summary
Veteran of Chinese health regulation outlines ABC's of the changes sweeping the vast nation at PharmAsia Summit.
You may also be interested in...
How Bayer Secured the Top-Spot in China: An Interview with Liam Condon
A focus on older, primary care brands--initially running contrary to Bayer Schering's group strategy post-merger--was key to the company's reaching its leadership position in China. Liam Condon, Managing Director of Bayer HealthCare China, talks about the group's commercial success to date and its future plans, particularly to build up its R&D presence.
How Bayer Secured the Top-Spot in China: An Interview with Liam Condon
A focus on older, primary care brands--initially running contrary to Bayer Schering's group strategy post-merger--was key to the company's reaching its leadership position in China. Liam Condon, Managing Director of Bayer HealthCare China, talks about the group's commercial success to date and its future plans, particularly to build up its R&D presence.
Primary Care Focus Is Key To Bayer's Leading Position In China
Bayer Schering Pharma didn't become the number one health care company in China simply through the merger of Bayer and compatriot Schering AG in 2006. "The pure act of merging would not have been enough; we would only have been number six" in China, explains Liam Condon, managing Director of Bayer HealthCare China, which reported 2008 sales of over $750 million and over 50 percent growth